Burning Rock, a Chinese Cancer Test Developer, Seeks $100 Million IPO

Burning Rock has developed 13 NGS-based tests for various cancers and boasts of collaborations with multinational pharma companies.

Anna Vodopyanova
    May 24, 2020 10:00 AM  PT
Burning Rock, a Chinese Cancer Test Developer, Seeks $100 Million IPO
author: Anna Vodopyanova   

China's Burning Rock Biotech Ltd. hopes to beat the new bill that would require foreign companies seeking IPO to disclose their audits by U.S. standards. The cancer test company has officially filed for a U.S. listing of up to $100 million.

With a mission to "guard life via science," Burning Rock provides next-generation sequencing-based cancer therapy selection tests used to assist physicians in determining therapy for oncology patients. The company's market share in China in terms of patients tested in 2019 was 26.7%, the largest among peers, according to China Insights Consultancy (CIC) cited in the prospectus.

Founded in 2014 and based in Guangzhou, Burning Rock's now offers 13 NGS-based tests applicable to various cancers including lung, gastrointestinal, prostate, and breast cancer, using both tissue and liquid biopsy samples. The company has amassed a database of 185,000 test results and is now building a "cloud-based cancer genomic data ecosystem that facilitates the broader exchange of real-time clinically actionable genomic data among physicians," according to the filing.

Burning Rock also said in the filing with the SEC that it has collaborated on clinical trials and research with global pharma companies including AstraZeneca (NYSE: AZN), Bayer (ETR: BAYN), Johnson & Johnson (NYSE: JNJ), Sino Biopharm (HKEX: 1177), CStone Pharmaceuticals (HKEX: 2616), and BeiGene (HKEX: 6160; Nasdaq: BGNE). Its lab is certified by both the CLIA in the U.S. and the NCCL in China.

For 2019, Burning Rock reported revenues of $53.9 million, an increase of 82.7% year-over-year. Net loss last year narrowed 5% to $23.9 million, the filing said. For the first quarter, impacted by the Covid-19 outbreak, the company reported revenues of $9.5 million on losses of $7.4 million. As of March 31, Burning Rock had $51.3 million in cash and cash equivalents.

The company said it intends to use the proceeds from its IPO for the development of early cancer detection tests and to obtain NMPA approvals for additional products and trials.

The company had filed confidentially in November 2019, before the Sino-U.S. tensions intensified, as reported by Renaissance Capital. Morgan Stanley & Co. LLC, BofA Securities Inc., Cowen and Company LLC, CMB International Capital Ltd., and Tiger Brokers (NZ) Ltd. are securing the deal.

Burning Rock hopes to list its ADSs on the Nasdaq Global Market under the symbol "BNR."